NEW YORK (GenomeWeb News) — Xoma today said it will create monoclonal antibody agents for SRI International as part of that company’s deal with the National Institute of Allergy and Infectious Disease.
 
Xoma said the firms are still negotiating their contract, which will span 5 years and could be worth as much as $28.1 million. The company added that, if the full contract is awarded it will bring to $60 million the total amount of government contracts it has received since 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.